NCT00258271View on ClinicalTrials.gov

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Leukemia
Interventions
BIOLOGICAL

filgrastim

DRUG

cladribine

DRUG

cytarabine

DRUG

imatinib mesylate

Trial Locations (1)

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT00258271 - Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter